Tables

Table 1–The four parts of the tuberculosis (TB)–HIV co-infection survey sent to European Centre for Disease Prevention and Control TB contact points in European Union/European Economic Area countries

Part

Title

Description

1

Information on the national TB surveillance system

This section focussed on whether TB was notifiable in the country, the geographic coverage of the TB surveillance system, population groups that were under-reported and the information collected for a reported case

2

Practices and possibilities of collecting HIV status among TB patients

Starting with the question of whether information on co-infection status was available for individual TB cases reported to the national surveillance system, the questions assessed how this information was obtained, the completeness of this information, and advantages and disadvantages of the way the information was obtained

3

Guidance on, barriers to and drivers of TB–HIV co-infection

This section included questions on resources for TB–HIV co-infection surveillance in addition to those for TB surveillance separately, the availability of national guidelines for diagnosis and treatment of TB and TB–HIV, testing/screening practices and estimates for the proportion of TB patients tested for HIV, collaborative TB–HIV projects, and perceived support and barriers

4

The burden of TB–HIV co-infection

Assessing the definition of co-infection used for reporting purposes, the burden in terms of total number and proportion of TB cases co-infected with HIV, as well as the number of co-infected cases by sex, <15 and >15 yrs of age, with drug resistance, under DOT, who completed treatment, and who died

DOT: directly observed therapy.

Table 2–Collection of HIV status in tuberculosis (TB) surveillance systems in European Union/European Economic Area countries

Table 4–Number and proportion of tuberculosis patients co-infected with HIV in European Union/European Economic Area countries, and proportion by demographic and clinical characteristics

Country

Patients n (%)

Year

Males n

≥15 yrs of age %

MDR %

DOT %

Died %

Austria

NA

NA

NA

NA

NA

NA

NA

Belgium

52 (5.1)

2007

50

98

6

6

Cyprus

0 (0.0)

2007

Czech Republic

7 (0.8)

2008

71

100

14

71

14

Denmark

7 (1.0)

2008

71

100

0

14

Estonia

41 (10.5)

2007

88

100

20

100

27

Finland

6 (1.0)

2009

50

France#

373 (5.9)

2002

89

Germany

NA

NA

NA

NA

NA

NA

NA

Iceland

2 (15.4)

2006

0

100

0

0

0

Ireland

16 (3.3)

2007

38

100

0

0

0

Latvia

50 (4.6)

2007

72

100

8

100

18

Lithuania

21 (0.9)

2007

93

100

10

71

29

Luxembourg

NA

NA

NA

NA

NA

NA

NA

Malta

5 (9.4)

2008

100

100

0

100

0

Norway

NA

NA

NA

NA

NA

NA

NA

Poland#

35 (0.4)

2008

77

100

0

8

Portugal

383 (13.9)

2008

76

99

1

75

14

Romania

202 (1)

2008

56

98

5

100

17

Slovakia

0 (0.0)

2007

Slovenia

0 (0.0)

2008

Spain

508 (6.0)

2008

78

99

Sweden

NA

NA

NA

NA

NA

NA

NA

The Netherlands

37 (3.7)

2008

9

UK

641 (8.2)

2005

55

100

1

MDR: multidrug resistance; DOT: directly observed treatment; NA: not available because HIV status is not collected in the TB surveillance system. #: HIV status is not collected in the TB surveillance system (figures are estimates based on the number of AIDS cases reported with TB as an AIDS-defining illness).